Monitor enrollment progress in the PRIME study and any subsequent U.S. regulatory pathway updates. Without financial data, near-term stock movement is likely driven by binary clinical/regulatory catalysts rather than fundamentals.
Price Chart
Executive Summary
Onconetix provided a Q1 2026 operational update highlighting new clinical publications for Proclarix®, initiation of the PRIME study with Labcorp, and European commercial expansion. No financial results were disclosed, and the company did not report revenue or EPS, making this a non-financial pipeline update.
Key Facts
- Two new peer-reviewed publications in BMC Cancer and Cancers reinforce Proclarix® performance in reducing overdiagnosis and unnecessary biopsies.
- PRIME study initiated with Labcorp to evaluate Proclarix® in the U.S. market; up to 500 men to be enrolled.
- European commercial expansion: ~100 Proclarix® tests conducted in Q1 2026 via a UK screening initiative; collaboration partner identified in Turkey.
- No financial results (revenue, EPS, cash position) were disclosed in the press release.
Financial Impact
No financial figures disclosed; impact depends on future commercialization milestones.
Risk Factors
- Proclarix® is not yet approved for sale in the U.S.; clinical validation and regulatory pathway remain uncertain.
- No revenue or cash runway disclosed; capital needs may require future dilutive financing.
- Historical stock performance shows extreme volatility and negative drift post-filing; prior bullish calls have underperformed significantly.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294088 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | DEFA14A / 8-K | $0.6374 $0.6549 | ▲ +2.75% | ▲ +2.64% | $0.7440 (+16.72%) |
Sep 14, 2026 18d ago | 8-K | $0.6374 $0.6549 | ▼ −2.75% | ▼ −2.64% | $0.7440 (−16.72%) |
Sep 14, 2026 18d ago | 425 | $0.6374 $0.6549 | ▼ −2.75% | ▼ −2.64% | $0.7440 (−16.72%) |
Sep 4, 2026 28d ago | EFFECT | $1.02 $0.6374 | ▲ +37.51% | ▲ +36.30% | $0.7440 (+27.06%) |
Sep 3, 2026 29d ago | 425 | $0.7390 $0.7564 | ▲ +2.35% | ▲ +3.50% | $0.7440 (+0.68%) |
Aug 31, 2026 4w ago | S-1/A | $0.6528 $0.8132 | ▼ −24.57% | ▼ −24.49% | $0.7440 (−13.97%) |
Aug 12, 2026 7w ago | S-1 | $0.8920 $0.7110 | ▲ +20.29% | ▲ +19.85% | $0.7440 (+16.59%) |
Jul 29, 2026 9w ago | 8-K | $0.7864 $0.9037 | ▼ −14.92% | ▼ −11.29% | $0.7440 (+5.39%) |
Jul 7, 2026 12w ago | 425 | $1.07 $0.8487 | ▼ −20.68% | ▼ −21.23% | $0.7440 (−30.47%) |
Jun 17, 2026 15w ago | EFFECT | $0.9949 $1.00 | ▼ −0.51% | ▼ −1.55% | $0.7440 (+25.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access